S. Lawn, S. Butera, and T. Folks, Contribution of Immune Activation to the Pathogenesis and Transmission of Human Immunodeficiency Virus Type 1 Infection, Clinical Microbiology Reviews, vol.14, issue.4, pp.753-777, 2001.
DOI : 10.1128/CMR.14.4.753-777.2001

S. Patterson, P. Moran, E. Epel, E. Sinclair, M. Kemeny et al., Cortisol patterns are associated with T cell activation in HIV.PLoS One Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis, AIDS, vol.823, issue.725, pp.634291059-1067, 2009.

J. Brenchley, D. Price, T. Schacker, T. Asher, G. Silvestri et al., Microbial translocation is a cause of systemic immune activation in chronic HIV infection, Nature Medicine, vol.174, issue.12, pp.20061365-71
DOI : 10.1038/nm1511

G. Marchetti, A. Cozzi-lepri, E. Merlini, G. Bellistrì, A. Castagna et al., ICONA Foundation Study Group Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count, AIDS Jul, vol.1725, issue.11, pp.1385-94, 2011.

P. Van-de-berg, K. Heutinck, R. Raabe, R. Minnee, S. Young et al., Human Cytomegalovirus Induces Systemic Immune Activation Characterized by a Type 1 Cytokine Signature, The Journal of Infectious Diseases, vol.202, issue.5, pp.690-699, 2010.
DOI : 10.1086/655472

S. Lang, M. Mary-krause, and L. Cotte, Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus???Infected Patients<subtitle>A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4</subtitle><alt-title>Antiretroviral Drugs, Risk of MI, and HIV</alt-title>, Archives of Internal Medicine, vol.170, issue.14, pp.1228-1266, 2010.
DOI : 10.1001/archinternmed.2010.197

C. Bavinger, E. Bendavid, K. Niehaus, R. Olshen, I. Olkin et al., Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review, PLoS ONE, vol.13, issue.8, p.59551, 2013.
DOI : 10.1371/journal.pone.0059551.s001

K. Armah, K. Mcginnis, J. Baker, C. Gibert, A. Butt et al., HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation, Altered Coagulation, and Monocyte Activation, Clinical Infectious Diseases, vol.55, issue.1, pp.126-162, 2012.
DOI : 10.1093/cid/cis406

V. Triant, H. Lee, C. Hadigan, and S. Grinspoon, Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.7, pp.2506-2512, 2007.
DOI : 10.1210/jc.2006-2190

D. Klein, L. Hurley, C. Quesenberry, . Jr, and S. Sidney, Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV-1 Infection?, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.30, issue.5, pp.471-477, 2002.
DOI : 10.1097/00126334-200208150-00002

S. Shoptaw, R. Stall, J. Bordon, U. Kao, C. Cox et al., Cumulative exposure to stimulants and immune function outcomes among HIV-positive and HIV-negative men in the Multicenter AIDS Cohort Study, International Journal of STD & AIDS, vol.96, issue.8
DOI : 10.1258/ijsa.2012.011322

D. Fuster, D. Cheng, E. Quinn, K. Armah, R. Saitz et al., Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems, AIDS, vol.28, issue.7, 2014.
DOI : 10.1097/QAD.0000000000000184

C. Larsen, G. Pialoux, and D. Salmon, Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, Euro surveill, vol.13, 2004.

K. High, M. Brennan-ing, D. Clifford, M. Cohen, J. Currier et al., HIV and Aging, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.60, issue.37 1, pp.1-18, 2012.
DOI : 10.1097/QAI.0b013e31825a3668

P. Morlat, Prise en charge médicale des personnes vivant avec le VIH. Recommandations du groupe d'experts. Rapport 2013, 2013.

S. Lang, M. Mary-krause, A. Simon, M. Partisani, J. Gilquin et al., HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals; for the French Hospital Database on HIV (FHDH)?ANRS CO4a, pp.600-606

A. Chang, C. Kuller, L. Goetz, M. Leaf, D. Rimland et al., Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease, Arch Intern Med, vol.171, issue.8, pp.737-780, 2011.

K. Lichtenstein, C. Armon, and K. Buchacz, T Cell Count Is a Risk Factor for Cardiovascular Disease Events in the HIV Outpatient Study, Clinical Infectious Diseases, vol.51, issue.4, pp.435-447, 2010.
DOI : 10.1086/655144

M. Lawe, N. Friis-moller, and W. El-sadr, The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study, HIV Medicine, vol.2, issue.2, pp.218-248, 2006.
DOI : 10.1086/378131

D. Sr, R. Vasan, M. Pencina, P. Wolf, M. Cobain et al., General cardiovascular risk profile for use in primary care: the Framingham Heart study, Circulation, vol.117, pp.743-753, 2008.

P. Hsue, J. Lo, A. Franklin, A. Bolger, J. Martin et al., Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.Circulation, pp.1603-1611, 2004.

S. Piconi, S. Parisotto, G. Rizzardini, S. Passerini, P. Meraviglia et al., Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals, AIDS, vol.27, issue.3, pp.381-390, 2013.
DOI : 10.1097/QAD.0b013e32835abcc9

D. Mariano-goulart, J. Jacquet, N. Molinari, A. Bourdon, M. Benkiran et al., Should HIV-infected patients be screened for silent myocardial ischaemia using gated myocardial perfusion SPECT?, European Journal of Nuclear Medicine and Molecular Imaging, vol.17, issue.10, pp.2013271-2013280
DOI : 10.1007/s00259-012-2262-1

H. Recommandations and . Prévention, Diagnostic et Traitement de l'ostéoporose, HAS. Juillet, 2006.

F. Collin, X. Duval, L. Moing, and V. , Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults, AIDS, vol.23, issue.8, pp.1021-1024, 2009.
DOI : 10.1097/QAD.0b013e3283292195

URL : https://hal.archives-ouvertes.fr/inserm-00374705

H. Dong, Y. Cortés, S. Shiau, and M. Yin, Osteoporosis and fractures in HIV/hepatitis C virus coinfection, AIDS, vol.28, issue.14, 2014.
DOI : 10.1097/QAD.0000000000000363

R. Bedimo, N. Maalouf, S. Zhang, H. Drechsler, and P. Tebas, Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents, AIDS, vol.26, issue.7, pp.825-856, 2012.
DOI : 10.1097/QAD.0b013e32835192ae

S. Jones, D. Restrepo, A. Kasowitz, and D. Korenstein, Risk factors for decreased bone density and effects of HIV on bone in the elderly, Osteoporosis International, vol.90, issue.7, pp.913-921, 2007.
DOI : 10.1007/s00198-007-0524-8

M. Bolland, A. Grey, G. Gamble, and I. Reid, Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, vol.92, issue.12, pp.4522-4528, 2007.
DOI : 10.1210/jc.2007-1660

C. Cazanave, M. Dupon, V. Lavignolle-aurillac, N. Barthe, S. Lawson-ayayi et al., Reduced bone mineral density in HIV-infected patients: prevalence and associated factors, AIDS, vol.22, issue.3, pp.395-402, 2008.
DOI : 10.1097/QAD.0b013e3282f423dd

URL : https://hal.archives-ouvertes.fr/inserm-00186715

K. Briot, B. Cortet, and T. Thomas, Actualisation 2012 des recommandations françaises du traitement médicamenteux de l'ostéoporose post ménopausique. Revue du rhumatisme, 2012.

A. Papaioannou, S. Msc, . Morin, A. M. Msc, . Cheung et al., 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary, Canadian Medical Association Journal, vol.182, issue.17, pp.1864-1873, 2010.
DOI : 10.1503/cmaj.100771

C. Howard, M. , and N. Chalasani, Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals, Ann. N.Y. Sci, pp.1281-106, 2013.

J. Sutinen, A. Hakkinen, and J. Westerbacka, Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy, AIDS, vol.16, issue.16, pp.183-93, 2002.
DOI : 10.1097/00002030-200211080-00011

L. Slama, C. Le-camus, and L. Serfaty, Metabolic disorders and chronic viral disease: The case of HIV and HCV, Diabetes & Metabolism, vol.35, issue.1, pp.1-11, 2009.
DOI : 10.1016/j.diabet.2008.08.003

M. Machado, A. Oliveira, C. ?. Pinto, and H. , Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors, Hepatology, vol.48, issue.Suppl 1, pp.71-78, 2010.
DOI : 10.1002/hep.23619

G. Guaraldi, N. Squillace, and C. Stentarelli, Nonalcoholic Fatty Liver Disease in HIV???Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors, Clinical Infectious Diseases, vol.47, issue.2, pp.250-256, 2008.
DOI : 10.1086/589294

V. Soriano, M. Puoti, P. Garcia-gascó, J. Rockstroh, Y. Benhamou et al., Antiretroviral drugs and liver injury, AIDS, vol.22, issue.1, pp.1-13, 2008.
DOI : 10.1097/QAD.0b013e3282f0e2fd

M. Dallapiazza, V. Amorosa, R. Localio, J. Kostman, L. Re et al., Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus infection: assessment using transient elastometry and the role of HCV genotype 3, BMC Infect Dis Clin Infect Dis, vol.1042, issue.70, pp.1032-1039, 2006.

C. Castellares, P. Barreiro, and L. Martin-carbonero, Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome, Journal of Viral Hepatitis, vol.10, issue.0, pp.165-172, 2008.
DOI : 10.1016/S0168-8278(98)80198-0

C. K. Argo, P. G. Northup, A. M. Al-osaimi, and S. H. Caldwell, Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis, Journal of Hepatology, vol.51, issue.2, pp.371-379, 2009.
DOI : 10.1016/j.jhep.2009.03.019

D. Nunes, C. Fleming, G. Offner, D. Craven, O. Fix et al., Noninvasive Markers of Liver Fibrosis Are Highly Predictive of Liver-Related Death in a Cohort of HCV-Infected Individuals With and Without HIV Infection, The American Journal of Gastroenterology, vol.9, issue.6, pp.1346-53, 2010.
DOI : 10.1038/ajg.2009.746

H. Al-mohri, C. Cooper, T. Murphy, and M. Klein, Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients, HIV Medicine, vol.143, issue.6, pp.375-378, 2005.
DOI : 10.1097/00002030-200303280-00010

T. Kelleher, S. Mehta, and R. Bhaskar, Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index, Journal of Hepatology, vol.43, issue.1, pp.78-84, 2005.
DOI : 10.1016/j.jhep.2005.02.025

R. Sterling, E. Lissen, and N. Clumeck, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, vol.41, issue.6, pp.1317-1342, 2006.
DOI : 10.1002/hep.21178

A. Vallet-pichard, V. Mallet, and B. Nalpas, FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest, Hepatology, vol.13, issue.1, pp.32-38, 2007.
DOI : 10.1002/hep.21669

C. Wyatt, The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis, AIDS, vol.22, issue.14, pp.1799-1807, 2008.
DOI : 10.1097/QAD.0b013e32830e0152

F. Islam, J. Wu, J. Jansson, and D. Wilson, Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis, BMC Public Health, vol.22, issue.14, p.234, 2012.
DOI : 10.1097/QAD.0b013e32830e0152

A. Mocroft, O. Kirk, P. Reiss, D. Wit, and S. , Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients, AIDS, vol.24, issue.11, pp.1667-1678, 2010.
DOI : 10.1097/QAD.0b013e328339fe53

R. Scherzer, M. Estrella, and Y. Li, Association of tenofovir exposure with kidney disease risk in HIV infection, AIDS, vol.26, issue.7, pp.867-875, 2012.
DOI : 10.1097/QAD.0b013e328351f68f

P. Morlat, A. Vivot, and M. Vandenhende, Role of traditional Risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, 2004.
URL : https://hal.archives-ouvertes.fr/hal-01101114

R. Kalayjian, B. Lau, R. Mecchekano, and H. Crane, Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care, AIDS, vol.26, issue.15, 2012.
DOI : 10.1097/QAD.0b013e328357f5ed

C. Fux and C. A. Zgraggen, Effect of tenofovir on renal glomerular and tubular function, AIDS, vol.21, issue.11, pp.1483-1485, 2007.
DOI : 10.1097/QAD.0b013e328216f15b

J. Young, J. Schafer, and C. Fux, Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir, AIDS, vol.26, issue.5, pp.567-575, 2012.
DOI : 10.1097/QAD.0b013e32834f337c

L. Calza, F. Trapani, C. Salvadori, E. Magistrelli, and R. Manfredi, Incidence of renal toxicity in HIV-infected, antiretroviral-na??ve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir, Scandinavian Journal of Infectious Diseases, vol.25, issue.2, pp.147-154, 2013.
DOI : 10.1097/QAD.0b013e32834bba87

E. Deti, Chronic Renal failure in HIV-Infected Patients: Incidence and risk factors (ANRS CO3 Aquitaine Cohort, France), th Conférence on Retroviruses and Opportunistics Infections (CROI), 2010.

L. Jacobson, Proteinuria among HIV-Infected HAART recipients in the multicenters AIDS cohort study (MACS). 4th conference on HIV Pathogenesis and treatment and prevention Sydney, 2007.

J. Walboomers, M. Jacobs, M. Manos, F. Bosch, J. Kummer et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, The Journal of Pathology, vol.89, issue.1, pp.12-21, 1999.
DOI : 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

P. Ramanujam, K. Venkatesh, C. Barnett, T. Fietz, and M. , Study of human papillomavirus infection in patients with anal squamous carcinoma, Diseases of the Colon & Rectum, vol.39, issue.1, pp.37-46, 1996.
DOI : 10.1007/BF02048266

M. Frisch, On the etiology of anal squamous carcinoma, Dan Med Bull, vol.49, issue.3, pp.194-209, 2002.

M. Nathan, N. Singh, N. Garrett, N. Hickey, T. Prevost et al., Performance of anal cytology in a clinical setting when measured against histology and high-resolution anoscopy findings, AIDS, vol.24, issue.3, pp.373-382, 2010.
DOI : 10.1097/QAD.0b013e328333ab8e

A. Antinori, G. Arendt, J. Becker, B. Brew, and D. Byrd, Updated research nosology for HIV-associated neurocognitive disorders, Neurology, vol.69, issue.18, pp.1789-99, 2007.
DOI : 10.1212/01.WNL.0000287431.88658.8b

S. Simioni, M. Cavassini, J. Annoni, R. Abraham, A. Bourquin et al., Cognitive dysfunction in HIV patients despite long-standing suppression of viremia, AIDS, vol.24, issue.9, pp.1243-50, 2010.
DOI : 10.1097/QAD.0b013e3283354a7b

V. Valcour, &. Pasiri-sithinamsuwan, &. Scott-letendre, and &. Beau, Pathogenesis of HIV in the Central Nervous System, Current HIV/AIDS Reports, vol.4, issue.5, pp.54-60, 2011.
DOI : 10.1007/s11904-010-0070-4

R. Ellis, J. Badiee, F. Vaida, S. Letendre, R. Heaton et al., CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy, AIDS, vol.25, issue.14, pp.1747-51, 2011.
DOI : 10.1097/QAD.0b013e32834a40cd

J. Becker, L. Kingsley, J. Mullen, B. Cohen, and E. Martin, Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men, Neurology, vol.73, issue.16, pp.1292-1299, 2009.
DOI : 10.1212/WNL.0b013e3181bd10e7

W. Ej, B. Grund, K. Robertson, and B. Brew, Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons, Neurology, 2010.

J. Mccombe, P. Vivithanaporn, M. Gill, and C. Power, Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care, HIV Medicine, vol.49, issue.Suppl 3, pp.99-107, 2013.
DOI : 10.1111/j.1468-1293.2012.01043.x

S. Letendre, A. Paulino, E. Rockenstein, and A. Adame, Pathogenesis of Hepatitis C Virus Coinfection in the Brains of Patients Infected with HIV, (105) HAS. Prise en charge d'un épisode dépressif isolé de l'adulte en ambulatoire, pp.361-70, 2002.
DOI : 10.1086/519285

M. Whooley and G. Simon, Managing Depression in Medical Outpatients, New England Journal of Medicine, vol.343, issue.26, pp.1942-50, 2000.
DOI : 10.1056/NEJM200012283432607

E. Bing, M. Burnam, D. Longshore, J. Fleishman, C. Sherbourne et al., Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United StatesArch Gen Psychiatry, 2001.

C. Mathers and D. Loncar, Projections of Global Mortality and Burden of Disease from 2002 to 2030, PLoS Medicine, vol.52, issue.11, p.442, 2006.
DOI : 10.1371/journal.pmed.0030442.st007

J. Currier, A. Taylor, and F. Boyd, Coronary Heart Disease in HIV-Infected Individuals, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.33, issue.4, p.506, 2003.
DOI : 10.1097/00126334-200308010-00012

N. Obel, H. Thomsen, and G. Kronborg, Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study, Clinical Infectious Diseases, vol.44, issue.12, pp.1625-1631, 2007.
DOI : 10.1086/518285

F. Islam, J. Wu, D. Jansson, and . Wilson, Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis, HIV Medicine, vol.126, pp.453-468, 2012.
DOI : 10.1111/j.1468-1293.2012.00996.x

M. Martelli, C. Silveira, E. De-sousa, C. , F. Mde et al., Turchi MD Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIVinfected persons, ScientificWorldJournal, vol.2013, p.969281, 2013.

N. Friis-moller, R. Thiébaut, P. Reiss, and R. Weber, D study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

R. Agostino, Cardiovascular Risk Estimation in 2012: Lessons Learned and Applicability to the HIV Population, Journal of Infectious Diseases, vol.205, issue.suppl 3, pp.362-369
DOI : 10.1093/infdis/jis196

D. Socio, G. Parruti, G. Ricci, E. Maggi, P. Celesia et al., CISAI study group. Decreasing cardiovascular risk in HIV infection between, AIDS. Feb, vol.2028, issue.4, pp.609-621, 2005.

M. Durand, O. Sheehy, J. Baril, J. Lelorier, and C. Tremblay, Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec's public health insurance database (QPHID).5 th IAS conference on HIV pathogenesis and treatment. Cape Town, 2009.

S. Lang, M. Mary-krause, and L. Cotte, Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population, AIDS, vol.24, issue.8, pp.1228-1230, 2010.
DOI : 10.1097/QAD.0b013e328339192f

S. Worm, C. Sabin, and R. Weber, Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti???HIV Drugs (D:A:D) Study, The Journal of Infectious Diseases, vol.201, issue.3, pp.318-330, 2010.
DOI : 10.1086/649897

A. Choi, E. Vittinghoff, S. Deeks, C. Weekley, Y. Li et al., Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons, AIDS, vol.25, issue.10, pp.1289-1298, 2011.
DOI : 10.1097/QAD.0b013e328347fa16

M. Cruciani, V. Zanichelli, and G. Serpelloni, Abacavir use and cardiovascular disease events, AIDS, vol.25, issue.16, pp.1993-2004, 2011.
DOI : 10.1097/QAD.0b013e328349c6ee

J. Lake, D. Wohl, R. Scherzer, C. Grunfeld, P. Tien et al., Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study, AIDS Care, vol.83, issue.8, pp.929-967, 2011.
DOI : 10.1152/japplphysiol.01035.2007

G. Guaraldi, C. Stentarelli, S. Zona, G. Orlando, F. Carli et al., Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects, Atherosclerosis, vol.208, issue.1, pp.222-229, 2010.
DOI : 10.1016/j.atherosclerosis.2009.06.011

G. Vernon and A. Baranova, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Alimentary Pharmacology & Therapeutics, vol.11, issue.6 Pt 2, pp.274-285, 2011.
DOI : 10.1111/j.1365-2036.2011.04724.x

O. Jarrett, C. Wanke, R. Ruthazer, I. Bica, R. Isaac et al., Metabolic Syndrome Predicts All-Cause Mortality in Persons with Human Immunodeficiency Virus, AIDS Patient Care and STDs, vol.27, issue.5, pp.266-71, 2013.
DOI : 10.1089/apc.2012.0402

I. Brar, J. Shuter, A. Thomas, E. Daniels, and J. Absalon, A Comparison of Factors Associated With Prevalent Diabetes Mellitus Among HIV-Infected Antiretroviral-Naive Individuals Versus Individuals in the National Health and Nutritional Examination Survey Cohort, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.45, issue.1, pp.66-71, 2007.
DOI : 10.1097/QAI.0b013e318031d7e3

A. Butt, K. Mcginnis, M. Rodriguez-barradas, C. S. Simberkoff, M. Goetz et al., Veterans Aging Cohort StudyAIDS, HIV infection and the risk of diabetes mellitus, pp.1227-1261, 2009.

J. Capeau, V. Bouteloup, C. Katlama, J. Bastard, V. Guiyedi et al., Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment, AIDS, vol.26, issue.3, pp.303-317, 2012.
DOI : 10.1097/QAD.0b013e32834e8776

URL : https://hal.archives-ouvertes.fr/hal-00875222

H. Murata, P. Hruz, and M. Mueckler, The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy, Journal of Biological Chemistry, vol.275, issue.27, pp.20251-20255, 2000.
DOI : 10.1074/jbc.C000228200

A. Tripathi, J. Jerrell, A. Liese, J. Zhang, A. Rizvi et al., Association of Clinical and Therapeutic Factors with Incident Dyslipidemia in a Cohort of Human Immunodeficiency Virus???Infected and Non-Infected Adults: 1994???2011, ) (186) HAS. Dépistage de l'infection par le VIH en France-stratégies et dispositif de dépistage, p.417, 2009.
DOI : 10.1089/met.2013.0017

M. Fiandino, Etudes de Freins à la prise en charge par le médecin généraliste des patients vivant avec le VIH. 2014. (188) Lavoix A. Etat des lieux de la prise en charge en médecine générale des patients infectés par le VIH en Mayenne en 2012, 2013.

M. Alcaide, A. Parmigiani, S. Pallikkuth, M. Roach, and R. Freguja, Immune activation in HIV-infected aging women on antiretrovirals--implications for age-associated comorbidities: a cross-sectional pilot study Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort, J Acquir Immune Defic Syndr, vol.8, issue.5, p.63804, 2010.

D. Boulware, K. Hullsiek, C. Puronen, A. Rupert, J. Baker et al., Sereti I; INSIGHT Study Group. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death, J Infect Dis, vol.2034, issue.11, pp.1637-1683, 2011.

L. Kuller1, R. Tracy, W. Belloso, S. D. Wit, F. Drummond et al., Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection, PLoS Medicine, vol.180, issue.10, pp.51496-1508, 2008.
DOI : 10.1371/journal.pmed.0050203.sd002

T. Sainz, M. Alvarez-fuente, M. Navarro, L. Díaz, and P. Rojo, Subclinical Atherosclerosis and Markers of Immune Activation in HIV-Infected Children and Adolescents, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.65, issue.1, pp.42-51, 2014.
DOI : 10.1097/QAI.0b013e3182a9466a

T. Brown, K. Tassiopoulos, R. Bosch, C. Shikuma, and G. Mccomsey, Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy, Diabetes Care, vol.33, issue.10, pp.2244-2253, 2010.
DOI : 10.2337/dc10-0633

N. Funderburg, Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients, Current Opinion in HIV and AIDS, vol.9, issue.1, pp.80-86
DOI : 10.1097/COH.0000000000000019

Á. Borges, M. Silverberg, D. Wentworth, A. Grulich, G. Fätkenheuer et al., Predicting risk of cancer during HIV infection, AIDS, vol.27, issue.9, pp.1433-1474, 2013.
DOI : 10.1097/QAD.0b013e32835f6b0c

URL : https://hal.archives-ouvertes.fr/hal-01101192

S. Serrano-villar, C. Gutiérrez, A. Vallejo, B. Hernández-novoa, L. Díaz et al., The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression, Journal of Infection, vol.66, issue.1, pp.201357-66
DOI : 10.1016/j.jinf.2012.09.013

V. Leung, J. Gillis, J. Raboud, C. Cooper, R. Hogg et al., Predictors of CD4:CD8 Ratio Normalization and Its Effect on Health Outcomes in the Era of Combination Antiretroviral Therapy, PLoS ONE, vol.1, issue.10, p.77665, 2013.
DOI : 10.1371/journal.pone.0077665.t003

S. Serrano-villar, T. Sainz, S. Lee, P. Hunt, and E. Sinclair, HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality, PLoS Pathogens, vol.185, issue.5, p.1004078, 2014.
DOI : 10.1371/journal.ppat.1004078.s011

A. Tenorio, Y. Zheng, R. Bosch, S. Krishnan, B. Rodriguez et al., Soluble markers of inflammation and coagulation, but not T-cell activation, are predictors of non-AIDS-defining morbid events during suppressive antiretroviral treatmentEpub ahead of print] 4. Infection à papillomavirus 5. Herpès 6. Autres infections sexuellement transmissibles : ????????.????. d'inutilité,Diminution des facultés de concentration et de prise de décision, Idées suicidaires ou tentative de suicide Nb FDR fibrose Age>50; IMC>30;ATCD Diabete=OUI syndrome métabolique, J Infect Dis.Oui, 2014.

F. Nb, /. Asat, and G. Alat<1, TG>1,7;1;0); TTaille>102 And Sexe=Un Homme" And TTaille?0 ,TTaille>92 And Sexe=Une FemmeOr Chol HDL<1,3 And Sexe= "Une Femme, Lipodystrophie="Hypertrophie abdominale", type NrTI1="AZT" Or Type NrTI2="AZT" Or type INTI3="AZT" Or Type NrTI1="D4T" Or Type NrTI2="D4T" Or type INTI3=

F. Nb, Oui";ATCD fract=, Oui, vol.1

C. Hépatite, HVC Chronique active"; Prise Cortisone plus 3 mois="Oui, p.7

F. Nb, . Métabolique-ttaille?94-and, and . Sexe=, Un Homme"; TAsyst>130;1;0)

T. >1, Chol HDL<1 And Sexe=Un Homme";(Chol HDL < 1,3 And Sexe=Une Femme";Glycémie>5,6;1;0);TTaille?80 And Sexe=, Une Femme, vol.7

F. Nb, . Rénaux-tasyst>140-or-tadiasto>90-;-atcd-diabete=-age>60, C. Nadir, and A. Vih=, Supérieur à 400 copies";Hépatite C="HVC Chronique active";Type NrTI1="TFV" Or Type NrTI2="TFV" Or type IP="Atazanavir";1;0); ATCD calcul=, p.10000